BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
11,78 USD
arrow_downward
-1,54%(-0,18) 1 d.
13. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BVNRY…
Otvoriť
11,77 USD
Vysoká
11,78 USD
Nízka
11,77 USD
Trh. kap.
2,82 mld.
Priem. obj.
3,04 tis.
Objem
895,00
Pomer cena/zárobky
12,70
Max. za 52 týž.
13,00 USD
Min. za 52 týž.
8,67 USD
Výnosy na akciu
0,93 USD
Beta
1,45
Akcie v obehu
237,82 mil.
Počet zamestnancov
2 tis.
Otvoriť
11,77 USD
Vysoká
11,78 USD
Nízka
11,77 USD
Trh. kap.
2,82 mld.
Priem. obj.
3,04 tis.
Objem
895,00
Pomer cena/zárobky
12,70
Max. za 52 týž.
13,00 USD
Min. za 52 týž.
8,67 USD
Výnosy na akciu
0,93 USD
Beta
1,45
Akcie v obehu
237,82 mil.
Počet zamestnancov
2 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
GlobeNewswire
·
pred 1 dňom
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Informácie o subjekte Bavarian Nordic A/S - ADR
Generálny riaditeľPaul Chaplin
Zamestnanci1,91 tis.
Dátum založenia1. 7. 1992
Hlavné sídlo-
Odvetvie-